Parkwalk Advisors has returned to back a $46m round for PhoreMost, weeks after the latter’s spinout Neophore attracted $21m in a series B.
PhoreMost, a UK-based biopharmaceutical spinout of University of Cambridge, closed a £33m ($46m) series B round featuring Parkwalk Advisors, the fund management subsidiary of commercialisation firm IP Group.
BGF led the round, which also attracted artificial intelligence-driven drug discovery company XtalPi and Astellas Venture Management, the investment arm of pharmaceutical company Astellas.
Trend Investment Group, O2H Ventures, Morningside Venutres and outgoing PhoreMost chairman Jonathan Milner also participated in the round.
Founded in 2014, PhoreMost has created a…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
